Sleeping Beauty ASX BSX, page-2064

My reading of it is that a small proportion of only one of our 26+ massive sulphide veins might be processed as a concentrate and sold in order to provide BSX's share of the capital requirements, was it around $60-75m or so, for the downstream processing and new concentrator. Then both concentrators would run to supply the downstream JV only.

In my opinion it would be malpractice to raise new capital and dilute existing holders ownership of the resource when the Company has the means to raise the capital through revenue streams which it is most capable of and equipped to achieve. If we demonstrate we are capable and equipped to achieve this it is also my opinion that we might find it easier to access cheap finance, say from a German bank or something similar, rather than being forced into a position to issue new shares.